Copyright: ©Author(s) 2026.
World J Gastrointest Oncol. Aug 15, 2026; 18(8): 118698
Published online Aug 15, 2026. doi: 10.4251/wjgo.118698
Published online Aug 15, 2026. doi: 10.4251/wjgo.118698
Table 5 Comparison of adverse reactions between the two groups, n (%)
| Group | Hand-foot syndrome | Disgust and vomiting | Diarrhea | Stomatitis | Bone marrow suppression | |
| Grade 1-4 | Grade 3 | |||||
| Control group (n = 60) | 20 (33.33) | 24 (40.00) | 16 (26.67) | 12 (20.00) | 27 (45.00) | 5 (8.33) |
| Experimental group (n = 60) | 18 (30.00) | 23 (38.33) | 15 (25.00) | 11 (18.33) | 25 (41.67) | 4 (6.67) |
| χ² | 0.154 | 0.035 | 0.044 | 0.054 | 0.136 | - |
| P value | 0.695 | 0.852 | 0.835 | 0.817 | 0.713 | 0.729 |
- Citation: Lou HC, Liu XH, Jin P, Wang JM, Liu B. Interaction between calcium channel blockers and capecitabine in colorectal cancer patients with hypertension. World J Gastrointest Oncol 2026; 18(8): 118698
- URL: https://www.wjgnet.com/1948-5204/full/v18/i8/118698.htm
- DOI: https://dx.doi.org/10.4251/wjgo.118698